HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

<ul>
<li>The discovery of Omicron has upset the market,and the main concern is that it could be highly contagious. However, it will take several months for new vaccines to be mass-produced.</li>
<li>We made our forecast on <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna Inc (MRNA US)</a>’s revenue according to different scenarios of Omicron.</li>
<li>We also analyzed the comparison between Moderna’s vaccines and its peers’ products as well as the related outlook.</li>
</ul>


The discovery of Omicron has upset the market,and the main concern is that it could be highly contagious. However, it will take several months for new vaccines to be mass-produced.
We made our forecast on Moderna Inc (MRNA US)’s revenue according to different scenarios of Omicron.
We also analyzed the comparison between Moderna’s vaccines and its peers’ products as well as the related outlook.


Moderna Inc (MRNA US) - Insights About the Performance in Front of Omicron

United States

Moderna, Inc. operates as a biotechnology company. The Company focuses on the discovery and development of messenger RNA therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Moderna (MRNA US)

Moderna Inc (MRNA US) - Insights About the Performance in Front of Omicron

This article analyzed the revenue forecast of Moderna according to the various scenarios of Omicron depending on its severity. We also analyzed...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)